Anti-apoptotic effect of umbilical cord cryoextract and its lyophilized form on L929 cells

The umbilical cord cryoextract (UCC) and its lyophilized form (LUCC) contain numerous biologically active components, including growth factors, cytokines, and other regulatory molecules, which may exert an anti-apoptotic effect on cells. This study aimed to determine whether these samples can reduce apoptosis levels in healthy cells, which is particularly relevant in scenarios where apoptosis may be induced by chemotherapeutic agents such as doxorubicin. To evaluate the potential protective effects of umbilical cord cryoextracts, the L929 cell line treated with doxorubicin, a known apoptosis inducer, was selected as a model for assessing the anti-apoptotic properties of UCC and LUCC. In the experiment, L929 cells were cultured in standard Dulbecco's Modified Eagle Medium (DMEM) with the addition of doxorubicin. Experimental results demonstrated that the addition of fetal bovine serum (FBS), UCC, and LUCC significantly reduced apoptosis levels in L929 cells compared to the group treated with doxorubicin alone. In samples with UCC and LUCC, apoptosis levels were comparable to those in the FBS group, indicating a potential supportive and anti-apoptotic effect of both forms of umbilical cord cryoextracts. These findings suggest that both the cryoextract and its lyophilized form may serve as effective agents for reducing apoptosis, maintaining the stability of their active components even post-lyophilization. The results support the potential use of umbilical cord cryoextracts in chemotherapy involving agents such as doxorubicin to mitigate apoptosis in healthy cells and reduce toxic side effects. Further research is needed to elucidate the mechanisms of action of these extracts and to assess their efficacy in vivo, which may open new opportunities for their application in oncology therapy and other medical fields.